| Identification | Back Directory | [Name]
1''-(2-Hydroxy-2-(6-methyl-1H-indol-3-yl)ethyl)-3,4-dihydrospiro[benzo[h]chromene-2,4''-piperidin]-4-ol | [CAS]
1214531-21-1 | [Synonyms]
1''-(2-Hydroxy-2-(6-methyl-1H-indol-3-yl)ethyl)-3,4-dihydrospiro[benzo[h]chromene-2,4''-piperidin]-4-ol
Spiro[2H-naphtho[1,2-b]pyran-2,4'-piperidine]-1'-ethanol, 3,4-dihydro-4-hydroxy-α-(6-methyl-1H-indol-3-yl)- | [Molecular Formula]
C28H30N2O3 | [MOL File]
1214531-21-1.mol | [Molecular Weight]
442.55 |
| Hazard Information | Back Directory | [Uses]
JBC117 is a novel anticancer lead compound targeting Pygo2 PHD. JBC117 can effectively antagonize the cell effect of β-catenin-dependent activity and inhibit the migration and invasion of cancer cells. JBC117 can induce apoptosis[1]. | [in vivo]
JBC117 (20 mg/kg/ day, subcutaneously injected for 14 days) shows antitumor activity in mouse xenotransplantation models of colon cancer and lung cancer[1].
| Animal Model: | Mouse xenograft models of colon and lung cancer[1] | | Dosage: | 20 mg/kg | | Administration: | s.c. for 14 days | | Result: | Reduced colon and lung tumor growth by 65% and 93%, respectively.
Increased apoptosis in the tumor sections.
|
| [References]
[1] Ali F, et al. Logical design of an anti-cancer agent targeting the plant homeodomain in Pygopus2. Cancer Sci. 2016 Sep;107(9):1321-8. DOI:10.1111/cas.12995 |
|
| Company Name: |
Chemenu Inc.
|
| Tel: |
+86-21-2022 2982 |
| Website: |
www.chemenu.com |
|